Rociletinib_Osimertinib for EGFR T790M-negative NSCLC [720p]
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Author: cancergrace
Added: 05/14/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts